Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early changes in [18F]FLT uptake after chemotherapy: an experimental study.

Helmut Dittmann1, Bernhard Matthias Dohmen, Rainer Kehlbach

  • 1Department of Nuclear Medicine, Eberhard-Karls-University, Roentgenweg 13, 72076 Tübingen, Germany. helmut.dittmann@med.uni-tuebingen.de

European Journal of Nuclear Medicine and Molecular Imaging
|October 25, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DGN procedural guideline for bone scintigraphy with SPECT and SPECT/CT in children and adolescents.

Nuklearmedizin. Nuclear medicine·2026
Same author

Exploring extended [<sup>18</sup>F]FDG kinetics in lymphoma with ultra-late LAFOV-PET/CT.

European journal of nuclear medicine and molecular imaging·2026
Same author

PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [<sup>177</sup>Lu]Lu-PSMA radiopharmaceutical therapy (RPT).

European journal of nuclear medicine and molecular imaging·2026
Same author

Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021.

International journal of cancer·2025
Same author

Low-activity [<sup>18</sup>F]-somatostatin receptor (SSTR) imaging using [<sup>18</sup>F]SiTATE on a long axial field-of-view PET/CT scanner.

EJNMMI physics·2025
Same author

One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.

European journal of nuclear medicine and molecular imaging·2025

3'-deoxy-3'-[(18)F]fluorothymidine (FLT) uptake changes differ based on chemotherapy drugs. Antimetabolites like 5-FU and methotrexate increase FLT uptake, while cisplatin decreases it, impacting its use for monitoring treatment early.

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Anticancer chemotherapy efficacy is often monitored by assessing tumor cell proliferation.
  • 3 '-deoxy-3 '-[(18)F]fluorothymidine ([(18)F]FLT) is a positron emission tomography (PET) tracer used to measure cell proliferation.
  • The early effects of different chemotherapy agents on [(18)F]FLT uptake require detailed investigation for accurate treatment monitoring.

Purpose of the Study:

  • To evaluate the utility of [(18)F]FLT for monitoring early chemotherapy effects on tumor cell proliferation.
  • To compare [(18)F]FLT uptake patterns in response to various chemotherapy drugs with different mechanisms of action.
  • To determine if [(18)F]FLT uptake changes correlate with cytotoxic effects and cell cycle distribution.

Main Methods:

Related Experiment Videos

  • Human esophageal squamous cell carcinoma (OSC-1) cells were treated with cisplatin (CDDP), 5-fluorouracil (5-FU), methotrexate (MTX), or gemcitabine (GEM).
  • Cells were incubated with varying drug doses and allowed to recover for 4, 24, or 72 hours before [(18)F]FLT or [(18)F]fluorodeoxyglucose (FDG) incubation.
  • Cytotoxic effects were assessed by cell counts, viability, clonogenic activity, and flow cytometry for cell cycle distribution.

Main Results:

  • [(18)F]FLT uptake increased 7-10 fold 24h after 5-FU or MTX treatment, independent of dose, reflecting activated DNA synthesis salvage pathways.
  • Gemcitabine showed a moderate increase in [(18)F]FLT accumulation, while cisplatin significantly reduced uptake, even at cytostatic concentrations.
  • [(18)F]FDG uptake did not significantly change after 5-FU or CDDP treatment, unlike [(18)F]FLT, highlighting drug-specific tracer responses.

Conclusions:

  • [(18)F]FLT uptake is modulated differently by various chemotherapeutic agents, contrasting with [(18)F]FDG.
  • Early increases in [(18)F]FLT uptake after antimetabolite treatment do not predict proliferation inhibition but indicate DNA synthesis pathway activation.
  • The distinct early [(18)F]FLT uptake changes induced by drugs like cisplatin necessitate careful consideration in PET-based treatment monitoring strategies.